An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

2008 ◽  
Vol 24 (5) ◽  
pp. 1529-1538 ◽  
Author(s):  
A. B. Gottlieb ◽  
B. Strober ◽  
J. G. Krueger ◽  
P. Rohane ◽  
J. B. Zeldis ◽  
...  
Keyword(s):  
Pilot Study ◽  
Open Label ◽  
Inflammatory Agent ◽  
Plaque Type ◽  
Anti Inflammatory

Fenbufen, a New Non-Steroidal Anti-Inflammatory Agent in Rheumatoid Arthritis, its Efficacy and Toxicity

1980 ◽  
Vol 8 (5) ◽  
pp. 333-338 ◽  
Author(s):  
Alfred Becker ◽  
Rex T Hoffmeister
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Half Life ◽  
Butanoic Acid ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Inflammatory Agent ◽  
Anti Inflammatory ◽  
Mild Toxicity

Fenbufen, a new butanoic acid derivative with anti-inflammatory properties, was evaluated in an open-label study. It was found that fenbufen was an effective anti-inflammatory agent with tolerable and acceptable potential side-effects. Its advantages appeared to be its long clinical half-life and relatively mild toxicity and/or allergic response.

Anti-Inflammatory Profile of Paricalcitol in Hemodialysis Patients: A Prospective, Open-Label, Pilot Study

2013 ◽  
Vol 53 (4) ◽  
pp. 421-426 ◽  
Author(s):  
Juan F. Navarro-González ◽  
Javier Donate-Correa ◽  
María L. Méndez ◽  
Mercedes Muros de Fuentes ◽  
Javier García-Pérez ◽  
...  
Keyword(s):  
Pilot Study ◽  
Hemodialysis Patients ◽  
Open Label ◽  
Anti Inflammatory ◽  
Inflammatory Profile

Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study

AIDS ◽  
2008 ◽  
Vol 22 (5) ◽  
pp. 653-655 ◽  
Author(s):  
Samir K Gupta ◽  
Raymond M Johnson ◽  
Chandan Saha ◽  
Kieren J Mather ◽  
Martha L Greenwald ◽  
...  
Keyword(s):  
Pilot Study ◽  
Endothelial Dysfunction ◽  
Inflammatory Agent ◽  
Anti Inflammatory

scholarly journals A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis

2003 ◽  
Vol 2 (1) ◽  
pp. 25-28 ◽  
Author(s):  
S.P. Conway ◽  
C. Etherington ◽  
D.G. Peckham ◽  
A. Whitehead
Keyword(s):  
Cystic Fibrosis ◽  
Pilot Study ◽  
Inflammatory Agent ◽  
Anti Inflammatory

scholarly journals An Open-Label, Single-Arm Pilot Study in Patients with Moderate to Severe Plaque-Type Psoriasis treated with Mesalazine

2014 ◽  
Vol 48 (1) ◽  
pp. 24-26
Author(s):  
Tarun Narang ◽  
Sanjeev Handa
Keyword(s):  
Pilot Study ◽  
Severity Index ◽  
Lipoxygenase Inhibitor ◽  
Open Label ◽  
Psoriasis Area Severity Index ◽  
Lipoxygenase Inhibitors ◽  
Plaque Type ◽  
Stable Plaque ◽  
Duration Of Disease ◽  
Significant Addition

ABSTRACT Lipoxygenase inhibitors have been reported to have a therapeutic effect in psoriasis. Mesalazine, a lipoxygenase inhibitor, similar to sulfasalazine was tried in psoriasis. Patients with moderate to severe psoriasis were treated with mesalazine in a dose of 400 mg thrice a day for 8 weeks. Patients were assessed for disease activity at the start of therapy, at 4 weeks and at 8 weeks using the psoriasis area severity index (PASI). Twenty-one patients (18 males and 3 females) of stable plaque psoriasis with a mean age of 42.3 years were included in the study. Duration of disease ranged from 3 months to 30 years. Mean body surface area involved was 36.3%. Of 19 patients who completed the study, 7 (36.8%) had ≥40% decline in PASI. Two patients did not respond to therapy. Mean baseline PASI decreased from 16.2 to 13.2 at 4 weeks and 10.1 at 8 weeks (p < 0.01). Both the values were statistically significant. Mesalazine can prove to be a significant addition or adjunct to the systemic therapies available for the treatment of psoriasis. How to cite this article Handa S, Narang T. An Open-Label, Single-Arm Pilot Study in Patients with Moderate to Severe Plaque-Type Psoriasis treated with Mesalazine. J Postgrad Med Edu Res 2014;48(1):24-26.

Sign in / Sign up

Export Citation Format

Share Document